Literature DB >> 8869749

A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices.

L E Hokin1, J F Dixon, G V Los.   

Abstract

Beginning at therapeutic concentrations (1-1.5mM), the anti-manic-depressive drug, lithium, stimulated the release of the major excitatory central neurotransmitter, glutamate, in monkey cerebral cortex slices in a time- and concentration-dependent manner, and this was associated with increased inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] accumulation. (+/-)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphoric acid (CPP), dizocilpine (MK-801), ketamine, and Mg(2+)-antagonists to the N-methyl D-aspartate (NMDA) receptor/channel complex selectivity inhibited lithium-stimulated Ins(1,4,5)P3 accumulation. Antagonists to cholinergic-muscarinic, alpha 1-adrenergic, 5-HT2-serotoninergic and H1-histaminergic receptors had no effect. Antagonists to non-NMDA glutamate receptors had no effect on lithium-stimulated Ins(1,4,5)P3 accumulation. Possible reasons for this are discussed. Similar results were obtained in mouse cerebral cortex slices. Carbetapentane, which inhibits glutamate release, inhibited lithium-induced Ins(1,4,5)P3 accumulation in this model. It is concluded that the primary effect of lithium in the cerebral cortex slice model is stimulation of glutamate release, which, via activation of the NMDA receptor, leads to Ca2+ entry. Ca2+ entry, in turn, activates phospholipase C. These effects may have relevance to the therapeutic action of lithium in the treatment of manic-depression, as well as its toxic effects, especially at lithium blood levels above 1.5mM. A general conclusion which can be drawn from these studies and earlier studies in our laboratory is that lithium potentiates the action of phospholipase C, whether this enzyme is activated by lithium-induced presynaptic release of neurotransmitter, such as glutamate, or by the addition of an exogenous neurotransmitter, such as acetylcholine. However, this does not appear to be due to a direct activation of phospholipase C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869749     DOI: 10.1016/0065-2571(95)00021-6

Source DB:  PubMed          Journal:  Adv Enzyme Regul        ISSN: 0065-2571


  10 in total

1.  Metabolomics Analyses of 14 Classical Neurotransmitters by GC-TOF with LC-MS Illustrates Secretion of 9 Cell-Cell Signaling Molecules from Sympathoadrenal Chromaffin Cells in the Presence of Lithium.

Authors:  Vivian Hook; Tobias Kind; Sonia Podvin; Mine Palazoglu; Carol Tran; Thomas Toneff; Stephanie Samra; Christopher Lietz; Oliver Fiehn
Journal:  ACS Chem Neurosci       Date:  2019-01-23       Impact factor: 4.418

Review 2.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

3.  Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

Review 4.  Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Authors:  Gin S Malhi; Michelle Tanious; Pritha Das; Carissa M Coulston; Michael Berk
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

5.  Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test.

Authors:  Todd D Gould; Kelley C O'Donnell; Eliot R Dow; Jing Du; Guang Chen; Husseini K Manji
Journal:  Neuropharmacology       Date:  2007-11-17       Impact factor: 5.250

Review 6.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

7.  Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia.

Authors:  Ji-Hyung Lee; Seon-Wook Kim; Jun-Hyeong Kim; Hyun-Jun Kim; JungIn Um; Da-Woon Jung; Darren R Williams
Journal:  Cells       Date:  2021-04-26       Impact factor: 6.600

8.  GRIN2B gene and associated brain cortical white matter changes in bipolar disorder: a preliminary combined platform investigation.

Authors:  Carissa Nadia Kuswanto; Min Yi Sum; Christopher Ren Zhi Thng; Yi Bin Zhang; Guo Liang Yang; Wieslaw Lucjan Nowinski; Yih Yian Sitoh; Chian Ming Low; Kang Sim
Journal:  Biomed Res Int       Date:  2013-12-30       Impact factor: 3.411

Review 9.  The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias.

Authors:  Alfredo Costa; Fabio Antonaci; Matteo Cotta Ramusino; Giuseppe Nappi
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

10.  Chronic lithium treatment alters the excitatory/ inhibitory balance of synaptic networks and reduces mGluR5-PKC signalling in mouse cortical neurons.

Authors:  Anouar Khayachi; Ariel Ase; Calwing Liao; Anusha Kamesh; Naila Kuhlmann; Lenka Schorova; Boris Chaumette; Patrick Dion; Martin Alda; Philippe Séguéla; Guy Rouleau; Austen Milnerwood
Journal:  J Psychiatry Neurosci       Date:  2021-06-02       Impact factor: 6.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.